摘要
目的观察养心氏片对慢性心力衰竭病人运动耐量以及生活质量的影响。方法选取2017年10月—2018年5月大连大学附属中山医院收治的80例慢性心力衰竭急性加重期病人,随机分为对照组(30例)、养心氏组(30例)、曲美他嗪组(10例)及养心氏+曲美他嗪组(10例),对照组采用优化药物达到最大耐受量。在优化药物达到最大耐受量基础上,曲美他嗪组加用曲美他嗪20mg,每日3次口服;养心氏组加用养心氏片3粒,每日3次口服;养心氏+曲美他嗪组加用养心氏片3粒,每日3次口服;曲美他嗪20mg,每日3次口服。各组观察期均为6个月,分别在治疗前后进行心肺运动试验(CPET)以及欧洲五维健康量表(EQ-5D)评分、堪萨斯心肌病问卷(KCCQ)评分。结果4组治疗前各观察指标差异无统计学意义。随访6个月,对照组心肺运动试验各参数、EQ-5D评分和KCCQ评分与治疗前相比,差异无统计学意义(P>0.05);养心氏组、曲美他嗪组及养心氏+曲美他嗪组心肺运动试验各参数、EQ-5D评分和KCCQ评分较治疗前明显提高,差异均有统计学意义(P<0.05);养心氏组、曲美他嗪组、养心氏+曲美他嗪组心肺运动各项指标、EQ-5D评分及KCCQ评分比较差异无统计学意义(P>0.05)。结论养心氏与曲美他嗪都可以在优化药物治疗基础上提高慢性心力衰竭病人运动耐量及生活质量,但两者联合较单一用药均无额外获益。
Objective To observe the effect of Yangxinshi on exercise tolerance and quality of life of patients with chronic heart failure.Methods Eighty patients with acute decompensated chronic heart failure who were admitted in Affiliated Zhongshan Hospital of Dalian University from October 2017 to May 2018 were randomly divided into control group(n=30),Yangxinshi group(n=30),trimetazidine group(n=10)and Yangxinshi+trimetazidine group(n=10).All patients received maximum tolerable dose of optimizing drug treatment.The patients in trimetazidine group received trimetazidine treatment(20 mg,3 times a day),patients in Yangxinshi group received Yangxinshi treatment(3 pills,3 times a day),and patients in Yangxinshi+trimetazidine group received trimetazidine(20 mg,3 times a day)and Yangxinshi treatment(3 pills,3 times a day).The observation period was 6 months.All patients were surveyed by cardiopulmonary exercise test,EQ-5 D and KCCQ before and 6 months after treatment.Results There was no significant difference in the parameters of cardiopulmonary exercise test,EQ-5 D score,and KCCQ score before and after treatment in the control group(P>0.05).The parameters of cardiopulmonary exercise test,EQ-5 D score,and KCCQ score in Yangxinshi group,trimetazidine group,and Yangxinshi+trimetazidine group were higher than those before treatment(P<0.05).There was no significant difference in the parameters of cardiopulmonary exercise test,EQ-5 D score,and KCCQ score between the 3 groups.Conclusion Both Yangxinshi and trimetazidine can significantly improve exercise tolerance and quality of life in patients with chronic heart failure on the basis of optimizing drug treatment.The combination of the two drugs has no additional benefit than any single drug.
作者
孙飞龙
袁炜婷
胡嘉慧
于勤
SUN Feilong;YUAN Weiting;HU Jiahui;YU Qin(Affiliated Zhongshan Hospital of Dalian University,Dalian 116001,Liaoning,China;Zunyi Medical University,Zunyi 563000,Guizhou,China)
出处
《中西医结合心脑血管病杂志》
2019年第17期2581-2584,共4页
Chinese Journal of Integrative Medicine on Cardio-Cerebrovascular Disease
关键词
慢性心力衰竭
养心氏片
心肺运动试验
运动耐量
生活质量
chronic heart failure
Yangxinshi
cardiopulmonary exercise test
exercise tolerance
quality of life
